相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?
Maria Luisa Gasparri et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2017)
Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review
Robert Cornelison et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival
Ahmedin Jemal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer
Maria Luisa Gasparri et al.
TUMOR BIOLOGY (2017)
Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression
Yuao Deng et al.
JOURNAL OF OVARIAN RESEARCH (2017)
Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival
Ahmedin Jemal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer
Wujian Zheng et al.
FRONTIERS IN PHARMACOLOGY (2017)
The disparate origins of ovarian cancers: pathogenesis and prevention strategies
Anthony N. Karnezis et al.
NATURE REVIEWS CANCER (2017)
A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells
Xi Han et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets
Vladimir A. Kuznetsov et al.
BMC GENOMICS (2017)
Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure
Elke Pogge von Strandmann et al.
TRENDS IN CANCER (2017)
Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells
Pinar Kanlikilicer et al.
CANCER RESEARCH (2016)
Is miR-34a a Well-equipped Swordsman to Conquer Temple of Molecular Oncology?
Ammad Ahmad Farooqi et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2016)
Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer
Zhentong Wei et al.
MEDICAL ONCOLOGY (2016)
miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin
Peng Guo et al.
ONCOLOGY REPORTS (2016)
PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells
Noemi Arrighetti et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2016)
MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2
Henan Zhao et al.
ONCOTARGET (2016)
IDO1 involvement in mTOR pathway: A molecular mechanism of resistance to mTOR targeting in medulloblastoma
Valentina Folgiero et al.
ONCOTARGET (2016)
Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Seiji Mabuchi et al.
GYNECOLOGIC ONCOLOGY (2015)
MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine
Y. Xiang et al.
ONCOGENE (2014)
The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
Zachary C. Dobbin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas
Yu-Quan Wang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2013)
Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells
Xin Fu et al.
FEBS LETTERS (2012)
Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications
Juan Carlos Montero et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance
Lingyun Yang et al.
ONCOLOGY REPORTS (2012)
Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization
J. Saadi Imam et al.
PLOS ONE (2012)
Dissecting PI3Kness: The Complexity of Personalized Therapy for Ovarian Cancer
Robert C. Bast et al.
CANCER DISCOVERY (2012)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines
Smriti Kumar et al.
JOURNAL OF OVARIAN RESEARCH (2011)
A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer
Ankur K. Nagaraja et al.
MOLECULAR ENDOCRINOLOGY (2010)
How do real tumors become resistant to cisplatin?
Piet Borst et al.
CELL CYCLE (2008)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
